Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsShunqiang Li, Ana M. González-Angulo, Xiaping He et al.|Cell Reports|2013Cited by 630
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaLoren Michel, Douglas R. Adkins, Jessica Ley et al.|Oral Oncology|2016Cited by 88
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|medRxiv|2020Cited by 4